This cohort study using data from the Nurses’ Health Study and Nurses’ Health Study II observed a 23% lower risk of ovarian cancer among current low-dose aspirin users compared with nonusers. Among the 205 498 women there were 1054 cases of incident epithelial ovarian cancer.
One common hypothesis about how Aspirin may prevent cancer is through its anti-inflammation activity. Chronic inflammation is known to increase the risk of certain types of cancer, including colorectal and ovarian cancers.
In the United States, almost half of adults aged 45 to 75 years take aspirin on a regular basis. For those who take aspirin regularly, there is a widespread belief in aspirin’s anticancer potential; in a 2015 study, 18% of Americans who took aspirin regularly said they were doing so to prevent cancer.
This current clinical trial tests whether aspirin may prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations. The women in the study have already decided to have preventive protective surgery and the trial will assess whether a low or standard dose of Aspirin for six months before the surgery reduces the incidence of pre-cancerous tissue damage in the resected ovaries and fallopian tubes.
No comments:
Post a Comment